Polypharmacology: the rise of multitarget drugs over combination therapies

Abstract

Future Medicinal ChemistryVol. 6, No. 5 EditorialPolypharmacology: the rise of multitarget drugs over combination therapiesMichela RosiniMichela RosiniDepartment of Pharmacy & Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. Search for more papers by this authorEmail the corresponding author at michela.rosini@unibo.itPublished Online:20 Mar 2014https://doi.org/10.4155/fmc.14.25AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: combination therapydesigned multiple ligandsmultifactorial diseasesmultitarget drugspolypharmacologyReferences1 Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet.12(1),56–68 (2011).Crossref, Medline, CAS, Google Scholar2 Hornberg JJ. Simple drugs do not cure complex diseases: the need for multi-targeted drugs. In: Designing Multi-Target Drugs. Morphy RM, Harris CJ (Eds). RSC Publishing, Cambridge, UK, 1–13 (2012).Google Scholar3 Ainsworth C. Networking for new drugs. Nat. Med.17(10),1166–1668 (2011).Crossref, Medline, CAS, Google Scholar4 Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel.13(3),297–309 (2010).Medline, CAS, Google Scholar5 Borisy AA, Zimmermann GR, Lehar J. Multicomponent therapeutics. In: Polypharmacology in Drug Discovery. Peters J-U (Ed.). Wiley, NJ, USA, 315–321 (2012).Google Scholar6 Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer10(2),130–137 (2010).Crossref, Medline, CAS, Google Scholar7 Monzon JG, Dancey J. Combination agents versus multi-targeted agents – pros and cons. In: Designing Multi-Target Drugs. Morphy RM, Harris CJ (Eds). RSC Publishing, Cambridge, UK, 155–180 (2012).Google Scholar8 Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem.51(3),347–372 (2008).Crossref, Medline, CAS, Google Scholar9 Evans BE, Rittle KE, Bock MG et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem.31(12),2235–2246 (1988).Crossref, Medline, CAS, Google Scholar10 Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today17(1–2),23–34 (2012).Crossref, Medline, CAS, Google Scholar11 Melchiorre C, Bolognesi ML, Minarini A, Rosini M, Tumiatti V. Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. J. Med. Chem.53(16),5906–5914 (2010).Crossref, Medline, CAS, Google Scholar12 Hu Y, Bajorath J. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment. AAPS J.15(1),104–111 (2013).Crossref, Medline, CAS, Google Scholar13 Manley PW, Zimmermann GR. Drug research leading to imatinib and beyond to nilotinib. In: Polypharmacology in Drug Discovery. Peters J-U (Ed.). Wiley, NJ, USA, 409–421 (2012).Google Scholar14 Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature462(7270),175–181 (2009).Crossref, Medline, CAS, Google Scholar15 Hopkins AL. Drug discovery: predicting promiscuity. Nature462(7270),167–168 (2009).Crossref, Medline, CAS, Google Scholar16 Peters JU. Polypharmacology – foe or friend? J. Med. Chem.56(22),8955–8971 (2013).Crossref, Medline, CAS, Google Scholar17 Bolognesi ML. Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem.20(13),1639–1645 (2013).Crossref, Medline, CAS, Google Scholar18 Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem.53(4),1413–1437 (2010).Crossref, Medline, CAS, Google Scholar19 Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics6(1),53–77 (2009).Crossref, Medline, CAS, Google Scholar20 Besnard J, Ruda GF, Setola V et al. Automated design of ligands to polypharmacological profiles. Nature492(7428),215–220 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByNigratine as dual inhibitor of necroptosis and ferroptosis regulated cell death24 March 2022 | Scientific Reports, Vol. 12, No. 1Progress and Development of Carbazole Scaffold Based as Potential Anti- Alzheimer Agents Using MTDL ApproachLetters in Drug Design & Discovery, Vol. 19, No. 12Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity13 September 2022 | Journal of Medicinal Chemistry, Vol. 65, No. 18The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancersBioorganic & Medicinal Chemistry, Vol. 70Kinetic and structural studies on the inhibition of acetylcholinesterase and butyrylcholinesterase by a series of multitarget-directed galantamine-peptide derivativesChemico-Biological Interactions, Vol. 365Caffeoyl malic acid is a potential dual inhibitor targeting TNFα/IL-4 evaluated by a combination strategy of network analysis-deep learning-molecular simulationComputers in Biology and Medicine, Vol. 145Recent development of BTK-based dual inhibitors in the treatment of cancersEuropean Journal of Medicinal Chemistry, Vol. 233Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs9 March 2022 | Pharmaceuticals, Vol. 15, No. 3Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity12 February 2022 | Journal of Medicinal Chemistry, Vol. 65, No. 4The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on DonepezilCurrent Topics in Medicinal Chemistry, Vol. 22, No. 5Computational approaches in drug designingMolecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A reviewEuropean Journal of Medicinal Chemistry, Vol. 228Strategies of Polypharmacology2 August 2022Polypharmacology in Clinical Applications: Neurological Polypharmacology2 August 2022Treating non-small cell lung cancer by targeting the PI3K signaling pathway5 June 2022 | Chinese Medical Journal, Vol. 135, No. 114-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads28 September 2021 | Journal of Medicinal Chemistry, Vol. 64, No. 19Combination Vs. Multi-target drugs: The Clash of the titans in the arena of drug discovery; An overview and in silico evaluation6 August 2021 | Research Journal of Pharmacy and TechnologyDesign, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure3 June 2021 | Journal of Medicinal Chemistry, Vol. 64, No. 12Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy8 June 2021 | Journal of Medicinal Chemistry, Vol. 64, No. 12Introducing the metacore concept for multi-target ligand design1 January 2021 | RSC Medicinal Chemistry, Vol. 12, No. 4Drug Re‐positioning Studies for Novel HIV‐1 Inhibitors Using Binary QSAR Models and Multi‐target‐driven In Silico Studies16 September 2020 | Molecular Informatics, Vol. 40, No. 2Prediction of Promiscuity Cliffs Using Machine Learning29 September 2020 | Molecular Informatics, Vol. 40, No. 1Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity5 November 2020 | Molecular Pharmaceutics, Vol. 17, No. 12Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)9 October 2020 | Angewandte Chemie International Edition, Vol. 59, No. 50Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs8 October 2020 | Angewandte Chemie, Vol. 132, No. 50Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review24 June 2020 | Drug Development Research, Vol. 81, No. 7Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease2 September 2020 | Molecules, Vol. 25, No. 17Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection9 July 2020 | Biomolecules, Vol. 10, No. 7X-ray Structure-Based Chemoinformatic Analysis Identifies Promiscuous Ligands Binding to Proteins from Different Classes with Varying Shapes27 May 2020 | International Journal of Molecular Sciences, Vol. 21, No. 11Structure-Based Discovery of Dual-Target Hits for Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptors: In Silico Studies and In Vitro Confirmation22 June 2020 | Molecules, Vol. 25, No. 12What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review19 December 2019 | Supportive Care in Cancer, Vol. 28, No. 4A Definition of “Multitargeticity”: Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis13 March 2020 | Frontiers in Chemistry, Vol. 8Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets8 October 2019 | Journal of Medicinal Chemistry, Vol. 63, No. 3Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents3 February 2020 | Molecules, Vol. 25, No. 3Futuristic Approaches Towards Designing of Isozyme-Selective Histone Deacetylase Inhibitors Against Zinc-Dependent Histone Deacetylases24 November 2020Identifying Promiscuous Compounds with Activity against Different Target Classes18 November 2019 | Molecules, Vol. 24, No. 22Triazole substituted metal-free, metallo-phthalocyanines and their water soluble derivatives as potential cholinesterases inhibitors: Design, synthesis and in vitro inhibition studyBioorganic Chemistry, Vol. 90A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's diseaseEuropean Journal of Medicinal Chemistry, Vol. 175Prediction of Different Classes of Promiscuous and Nonpromiscuous Compounds Using Machine Learning and Nearest Neighbor Analysis16 April 2019 | ACS Omega, Vol. 4, No. 4Lights and shadows of electrophile signaling: focus on the Nrf2-Keap1 pathwayFilippo Basagni, Cristina Lanni, Anna Minarini & Michela Rosini3 April 2019 | Future Medicinal Chemistry, Vol. 11, No. 7Recent Progress in Structure-Based Evaluation of Compound Promiscuity6 February 2019 | ACS Omega, Vol. 4, No. 2Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots22 January 2019 | ACS Omega, Vol. 4, No. 1Influence of the γ-carboline and carbazole pharmacophore moieties on anticholinesterase and antiradical activity of multifunctional agents for the treatment of neurodegenerative diseases8 November 2018 | Russian Chemical Bulletin, Vol. 67, No. 9Discovery of a novel multifunctional carbazole–aminoquinoline dimer for Alzheimer's disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection31 October 2017 | Medicinal Chemistry Research, Vol. 27, No. 3X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design5 January 2018 | ACS Omega, Vol. 3, No. 1Cheminformatics Approaches to Study Drug Polypharmacology9 June 2018Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimer’s Disease28 September 2017Multitargeting HeterocyclesComputational Methods to Discover Compounds for the Treatment of Chagas DiseasePolypharmacology in Drug Discovery8 December 2017Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitorsDawid Panek, Tomasz Wichur, Justyna Godyń , Anna Pasieka & Barbara Malawska19 September 2017 | Future Medicinal Chemistry, Vol. 9, No. 15Curcumin in Alzheimer’s disease: Can we think to new strategies and perspectives for this molecule?Pharmacological Research, Vol. 124Multiple target-centric strategy to tame inflammationGaganpreet Kaur & Om Silakari3 August 2017 | Future Medicinal Chemistry, Vol. 9, No. 12Focused design of polypharmacophoric neuroprotective compounds: Conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole12 May 2017 | Pure and Applied Chemistry, Vol. 89, No. 8Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregationElena Simoni, Manuela Bartolini, Izuddin F Abu, Alix Blockley, Cecilia Gotti, Giovanni Bottegoni, Roberta Caporaso, Christian Bergamini, Vincenza Andrisano, Andrea Cavalli, Ian R Mellor, Anna Minarini & Michela Rosini20 June 2017 | Future Medicinal Chemistry, Vol. 9, No. 10Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment30 March 2017 | Scientific Reports, Vol. 7, No. 1Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors24 October 2016 | Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 32, No. 1Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase21 October 2016 | Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 32, No. 1In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease9 September 2016 | Scientific Reports, Vol. 6, No. 1The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective9 November 2016 | PLOS ONE, Vol. 11, No. 11The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors30 August 2016 | Expert Opinion on Drug Discovery, Vol. 11, No. 10Nature-Inspired Multifunctional Ligands: Focusing on Amyloid-Based Molecular Mechanisms of Alzheimer's Disease26 October 2015 | ChemMedChem, Vol. 11, No. 12Polypharmacology: in silico methods of ligand design and developmentSamuel A McKie13 April 2016 | Future Medicinal Chemistry, Vol. 8, No. 5Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeuticsMichela Rosini, Elena Simoni, Roberta Caporaso & Anna Minarini15 April 2016 | Future Medicinal Chemistry, Vol. 8, No. 6Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy24 March 2016 | Molecules, Vol. 21, No. 4Weak-binding molecules are not drugs?—toward a systematic strategy for finding effective weak-binding drugs8 March 2016 | Briefings in Bioinformatics, Vol. 13Novel Tacrine–Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography29 December 2015 | Journal of Medicinal Chemistry, Vol. 59, No. 1One size does not fit all: Challenging some dogmas and taboos in drug discoveryChristina LL Chai & Péter Mátyus21 December 2015 | Future Medicinal Chemistry, Vol. 8, No. 1Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgyPharmacological Research, Vol. 101Avances en el diseño de fármacos asistido por computadoraEducación Química, Vol. 26, No. 3Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growthCancer Letters, Vol. 360, No. 2Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2Chao Ding, Cunlong Zhang, Mingli Zhang, Yu Zong Chen, Chunyan Tan, Ying Tan & Yuyang Jiang19 November 2014 | Future Medicinal Chemistry, Vol. 6, No. 16 Vol. 6, No. 5 Follow us on social media for the latest updates Metrics Downloaded 352 times History Published online 20 March 2014 Published in print April 2014 Information© Future Science LtdKeywordscombination therapydesigned multiple ligandsmultifactorial diseasesmultitarget drugspolypharmacologyFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download